{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:41:11Z","timestamp":1780472471132,"version":"3.54.1"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The aim of the present study was to investigate the effect of <jats:italic>CYP2D6<\/jats:italic> genotypes on mirtazapine and mianserin serum concentrations. Patients were included retrospectively from a therapeutic drug monitoring service. Multiple linear regression analysis was used to investigate the effect of <jats:italic>CYP2D6<\/jats:italic> genotype, age and sex on mirtazapine and mianserin concentration\u2010to\u2010dose (C\/D) ratio. The study included 2315 mirtazapine patients and 474 mianserin patients who were assigned to the genotype\u2010predicted phenotype groups of CYP2D6 poor metabolizers (PMs), intermediate metabolizers (IMs), normal metabolizers (NMs) and ultrarapid metabolizers (UMs). Multiple linear regression analysis revealed 18% and 14% higher mirtazapine C\/D ratio in CYP2D6 PMs and IMs, respectively, compared with NMs (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.004). For mianserin, the C\/D ratio was 80% and 45% higher in PMs and IMs, respectively, compared with NMs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The C\/D ratio in UMs did not differ from NMs for either drug (<jats:italic>p<\/jats:italic>\u2009\u2265\u20090.3). In conclusion, <jats:italic>CYP2D6<\/jats:italic> genotype was only associated with a minor change in mirtazapine serum concentration. The association between <jats:italic>CYP2D6<\/jats:italic> genotype and mianserin serum concentration was greater, with 80% higher mianserin C\/D ratio in CYP2D6 PMs compared with NMs.<\/jats:p>","DOI":"10.1111\/bcpt.70013","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:30:22Z","timestamp":1741350622000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association Between <i>CYP2D6<\/i> Genotypes and Serum Concentrations of Mirtazapine and Mianserin"],"prefix":"10.1111","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7300-5329","authenticated-orcid":false,"given":"Kristine","family":"Hole","sequence":"first","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital  Oslo Norway"},{"name":"Department of Life Sciences and Health Oslo Metropolitan University  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology Diakonhjemmet Hospital  Oslo Norway"},{"name":"Department of Pharmaceutical Biosciences, School of Pharmacy University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21671"},{"issue":"4","key":"e_1_2_9_3_1","first-page":"19","article-title":"The Pharmacologic Profile of Mirtazapine","volume":"57","author":"Boer T.","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"issue":"31","key":"e_1_2_9_4_1","first-page":"497","article-title":"Mianserin: Pharmacology and Clinical Aspects of an Effective Antidepressive Agents [Mianserin: Pharmakologie und Klinik Eines bew\u00e4hrten Antidepressivums]","volume":"111","author":"Demling J.","year":"1993","journal-title":"Fortschritte der Medizin"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)21446-X"},{"key":"e_1_2_9_6_1","unstructured":"FDA \u201cDrug Approval Package Remeron (Mirtazapine) Tablets \u201d accessed March 11 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/20\u2010415s003_Remeron.cfm."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011\u2010199713010\u201000005"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0026\u2010895x(24)12045\u20107"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.328"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)20103-3"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100043\u2010116492"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200038060\u201000001"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/0003088\u2010200948010\u201000005"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182664d98"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.1983.tb05875.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691\u2010199304000\u201000009"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691\u2010199304000\u201000008"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2009.02.006"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010004\u20100737\u20100"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2012.29"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000145341.30547.f0"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2174\/1386207323666200402081512"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.10.1830"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3643"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714\u2010199712000\u201000005"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691\u2010199802000\u201000002"},{"key":"e_1_2_9_27_1","unstructured":"\u201cGuidance on Bioavailability and Bioequivalence Studies for Orally Administered Drug Products \u2014 General Considerations \u201d (2003)."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010023\u201003611\u20103"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13944"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2903"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp\u20102019\u20100177"},{"issue":"3","key":"e_1_2_9_32_1","first-page":"58","article-title":"The Influence of Concentration of Micro\u2010RNA hsa\u2010miR\u2010370\u20103p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder","volume":"50","author":"Zastrozhin M. S.","year":"2020","journal-title":"Psychopharmacology Bulletin"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2022.2106214"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/bf00544361"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.121"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.70013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T01:57:06Z","timestamp":1744250226000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.70013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/bcpt.70013"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.70013","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"2024-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70013"}}